

AMENDMENTS TO THE CLAIMS

1-42. (Canceled)

43. (Previously Presented) An unformulated dry heparin-like glycosaminoglycan having a mean geometric diameter of 1-500 microns.

44-57. (Canceled)

58. (Previously Presented) A method for delivering a heparin-like glycosaminoglycan to a subject, comprising, administering to a pulmonary tissue of a subject the heparin-like glycosaminoglycan of claim 43.

59.-115. (Canceled)

116. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-200 microns.

117. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-53 microns.

118. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-5 microns.

119. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 5-53 microns.

120. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 53-106 microns.

121. (Previously Presented) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the heparin-like glycosaminoglycan is a heparin, a heparin sulfate, or a low molecular weight heparin.

122.-203. (Canceled)

204. (Currently Amended) AnThe unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan hashaving a mean geometric diameter of 10-500 microns.

205. (Canceled)

206. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 10-250 microns.

207. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 10-100 microns.

208. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 100-200 microns.

209. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 100-150 microns.

210. (Canceled)

211. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 20-53 microns.

212. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 53-75 microns.

213. (Currently Amended) The unformulated dry heparin-like glycosaminoglycan of claim 43204, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 75-106 microns.

214.-222. (Canceled)

223. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-50 microns.

224. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-20 microns.

225. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-100 microns.

226. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 1-250 microns.

227. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 5-200 microns.

228. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a mean geometric diameter of 5-30 microns.

229. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a tap density of 0.01 - 0.4 g/cm³.

230. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a tap density of greater than 0.4 g/cm³.

231. (New) The unformulated dry heparin-like glycosaminoglycan of claim 43, wherein the unformulated dry heparin-like glycosaminoglycan has a tap density of less than 0.4 g/cm³.

232. (New) A method for producing a therapeutic effect, comprising, administering to a pulmonary tissue of a subject the heparin-like glycosaminoglycan of claim 43.

233. (New) The method of claim 232, further comprising administering an additional therapeutic agent.

234. (New) The method of claim 233, wherein the additional therapeutic agent is selected from the group consisting of proteins, peptides, nucleic acids, and small organic molecules.